Neurology · 1997 · 217 citations · 19 references
MedicineNeurologyNeuroscienceDiagnostic ImagingNeuropathologyNeuroradiologyBasal GangliaBrain ImagingHuntington DiseaseNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic ImagingBasal Ganglia DamageBasal Ganglia DynamicsBasal Ganglia MorphometryBasal Ganglia PathologyGlobus Pallidus Internal SegmentHuntington Disease ImagingLongitudinal Change AnalysisTrinucleotide Repeat Disorders
Cross-sectional MRI studies demonstrating an association between caudate atrophy and symptom severity and duration of symptoms in patients with Huntington's disease (HD) have been assumed to reflect longitudinal changes in basal ganglia, but such neuropathologic progression has never been directly demonstrated. Subjects in the current study were 23 HD patients at various stages of the disorder who had two MRI images at least 10 months apart (mean interimage interval = 20.8 months). We measured volumes of caudate, putamen, and globus pallidus blind to the order of the images. For each structure, we calculated a change score by subtracting the volume obtained on the follow-up imaging from that obtained on the initial imaging. Results indicated significant decreases over time in caudate, putamen, and total basal ganglia volume. Age at onset and length of trinucleotide repeat correlated significantly with amount of volume change in caudate and total basal ganglia, even after controlling for length of interimage interval, duration of disease, and measures of symptom severity. Amount of change in basal ganglia structures was not significantly correlated with neurologic symptom severity at the time of the initial imaging or duration of symptoms. This is the first longitudinal MRI study to document progressive basal ganglia atrophy in HD, and suggests that quantitative neuroimaging with serial MRI may be useful in monitoring effectiveness of potential treatments. In addition, demonstration of greater rate of basal ganglia atrophy in patients with earlier symptom onset suggests that treatment effects may be more quickly observed in this subgroup of patients than in the general HD population.
19
Suzanne M. de la Monte, Jean‐Paul Vonsattel, Edward P. Richardson · Journal of Neuropathology & Experimental Neurology · 1988 · 427 citations
Medicine, Neurology, Neuroscience +16
Clinical and neuropathologic assessment of severity in Huntington's disease
Richard H. Myers, Jean Paul Vonsattel, Thomas J. Stevens et al. · Neurology · 1988 · 215 citations
Factors Associated With Slow Progression in Huntington's Disease
Richard H. Myers, Daniel S. Sax, Walter J. Koroshetz et al. · Archives of Neurology · 1991 · 210 citations
Medicine, Neurology, Pharmacology +17